<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578837</url>
  </required_header>
  <id_info>
    <org_study_id>OG-2-09-2920-VV</org_study_id>
    <nct_id>NCT01578837</nct_id>
  </id_info>
  <brief_title>Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes</brief_title>
  <acronym>R-KAT</acronym>
  <official_title>Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a combined Phase-I like (safety) and Phase-II like (efficacy) double blind
      randomized placebo controlled trial. The objective is to investigate whether the combination
      of AG and Rg3-enriched Korean Red ginseng added to conventional medical treatment are
      effective and safe in the long-term management of high blood pressure while managing type 2
      diabetes. Eighty-five subjects with type 2 diabetes and concomitant high blood pressure (key
      inclusion criteria: HbA1c ≥ 6.5%- ≤ 8.0%) will be recruited for the study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Mean 24 hour Systolic Ambulatory Blood Pressure at 12 weeks</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean 24 hour Diastolic Ambulatory Blood pressure at 12 Weeks</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Pressure</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Augmentation Index</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Wave Velocity at 12 Weeks</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in low-grade body inflammation (hs-CRP)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Calculated HOMA-Insulin Sensitivity</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat Bran</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 % Natural Wheat Bran capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginseng</intervention_name>
    <description>2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).</description>
    <arm_group_label>Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wheat Bran</intervention_name>
    <description>2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).</description>
    <arm_group_label>Wheat Bran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between the age of 40 and 75 years

          -  type 2 diabetes (at least 1 year duration, HbA1c ≥ 6.5%- ≤ 8.0%, treated with diet
             and/or oral hypoglycemic medications)

          -  clinically diagnosed and treated hypertension according to Canadian Diabetes
             Association Clinical Practice Guidelines

          -  normal thyroid, kidney and liver functions

          -  female subjects recruited for the study must be post-menopausal or had absence of
             menstruation for ≥ 1 year or is taking contraceptive precautions

        Exclusion Criteria:

          -  insulin therapy

          -  history of angina, myocardial infarction or stroke

          -  systolic blood pressure &gt;160 mmHg and/or diastolic blood pressure &gt;100 mmHg

          -  use of ginseng within 1 month start of study

          -  BMI &gt;35 kg/m2

          -  smoking cigarettes

          -  alcohol intake of &gt; 2 drinks/day

          -  recently given blood

          -  have an upcoming planned surgery

          -  GFR &lt;60 mL/min/1.73m2

          -  prolonged QT (&gt;20 ms) interval as assessed by ECG

          -  changes to use of natural health products that may effect blood pressure and/or
             diabetes

          -  weight change more than +/- 3 kg/month

          -  HIV infection, inflammatory bowel disease, celiac disease, heart disease, bleeding
             disorder, sleep disorder, arrhythmia

          -  pregnant or breastfeeding

          -  use of anticoagulant (excluding aspirin), antiplatelet, sedative, sympathomimetic,
             photosensitizing or anti-depressant drugs

          -  hormone replacement therapy, furosemide, morphine, glucocorticoids

          -  presence of any conditions which, in the opinion of the Qualified Investigator, might
             jeopardize the health and safety of the subject or study personnel, or adversely
             affect the study results

          -  known sensitivity or allergy to any test product or placebo ingredients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Vuksan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Jovanovski, MSc.</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>2597</phone_ext>
    <email>JovanovskiE@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison Komishon, MSc.(c)</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>5527</phone_ext>
    <email>KomishonA@smh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Jovanovski, MSc.</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>2597</phone_ext>
      <email>JovanovskiE@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Allison Komishon, MSc.(c)</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>5527</phone_ext>
      <email>KomishonA@smh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Vladimir Vuksan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Josse (Qualified Investigator), MD,FRCP(C)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamel S Kamel, M.B.B.Ch,FRCP(C)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Sievenpiper, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mi-Kyung Sung, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Jenkins, PhD, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dubrava University Hospital</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dario Rahelic, M.D., PhD</last_name>
      <phone>++38512902444</phone>
      <email>drahelic@kbd.hr</email>
    </contact>
    <investigator>
      <last_name>Dario Rahelic, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Michael's Hospital, Toronto</investigator_affiliation>
    <investigator_full_name>Vladimir Vuksan</investigator_full_name>
    <investigator_title>Dr. Vladimir Vuksan</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

